Fresenius Medical Care will pay over $231 million to resolve allegations of bribery and misconduct by the Securities and Exchange Commission and the Department of Justice.

The German company is accused of engaging in multiple schemes to make “improper payments,” including bribery, false consulting contracts, and falsifying documents, and the SEC said it paid government officials around the world nearly $30 million in bribes.

The SEC claimed Fresenius failed in certain cases to engage in basic measures to curb misconduct, such as providing proper anti-corruption training or performing due diligence on its agents.